Long-term safety and efficacy of intramyocardial adenovirus-mediated VEGF-DΔNΔC gene therapy eight-year follow-up of phase I KAT301 study

In phase I KAT301 trial, intramyocardial adenovirus-mediated vascular endothelial growth factor -D ΔNΔC (AdVEGF-D) gene therapy (GT) resulted in a significant improvement in myocardial perfusion reserve and relieved symptoms in refractory angina patients at 1-year follow-up without major safety conc...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Gene therapy 2022-05, Vol.29 (5), p.289-293
Hauptverfasser:	Leikas, Aleksi J., Hassinen, Iiro, Hedman, Antti, Kivelä, Antti, Ylä-Herttuala, Seppo, Hartikainen, Juha E. K.
Format:	Artikel
Sprache:	eng
Schlagworte:	42 42/44 59 59/78 631/61/201 692/699/75 Adenoviridae - genetics Adenoviridae Infections Adenoviruses Angina Angina pectoris Angina Pectoris - genetics Angina Pectoris - therapy Biomedical and Life Sciences Biomedicine Canada Cell Biology Follow-Up Studies Gene Expression Gene Therapy Gene Transfer Techniques Genetic Therapy - adverse effects Genetic Therapy - methods Human Genetics Humans Medical records Nanotechnology Patients Perfusion Safety Treatment Outcome Vascular endothelial growth factor Vascular Endothelial Growth Factor A - genetics Vascular Endothelial Growth Factor D - genetics
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!